CNMD Form 4: Kim Kelderman awarded RSUs and options with 1‑year vesting

Rhea-AI Filing Summary

Kim Kelderman, a director of CONMED Corporation (CNMD), was granted equity awards on 09/08/2025 consisting of 500 restricted stock units (RSUs) and options to purchase 6,227 shares of common stock. The RSUs represent the right to receive one share each and generally vest 100% after one year. The stock options have an exercise price of $53.83, vest 100% one year from the grant date, are exercisable beginning 09/08/2026 and expire 09/08/2035.

Following the reported grants, the filing shows beneficial ownership of 500 shares underlying RSUs and 6,227 option shares, held in a direct capacity. The Form 4 was signed on 09/09/2025 by a power of attorney on behalf of the reporting person.

Positive

• Clear alignment with shareholders: grants are equity‑based (RSUs and options) that vest over one year, promoting retention and alignment.
• Transparent terms: exercise price ($53.83), vesting schedule (100% after one year), exercisable date (09/08/2026) and expiration (09/08/2035) are disclosed.

Negative

• None.

Insights

Securities Analyst

TL;DR: Director received time‑vested RSUs and options, aligning compensation with future share performance and retention.

The grants are routine director equity awards: 500 RSUs and 6,227 options at $53.83, both vesting 100% after one year. The option term to 2035 provides a long runway for potential appreciation. These awards increase insider alignment with shareholders without immediate dilution until RSUs settle or options are exercised. The filing reports the holdings as direct beneficial ownership.

Corporate Governance Specialist

TL;DR: Standard long‑term incentive structure with clear vesting timelines and documented grant details.

The disclosure specifies the award plan (2025 Long‑Term Incentive Plan) and straightforward vesting (100% at one year) for both RSUs and options, which is consistent with retention-focused director compensation. Documentation of exercise price, exercisable date, and expiration enhances transparency. No dispositions or sales are reported.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Kelderman Kim

(Last) (First) (Middle)

C/O CONMED CORPORATION

11311 CONCEPT BOULEVARD

(Street)

LARGO FL 33773

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
CONMED Corp [ CNMD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
09/08/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
RSUs (Restricted Stock Units)	$0	09/08/2025		A		500		09/08/2026	09/08/2035	Common Stock	500	$0	500	D(1)(2)
Options To Purchase Common Stock	$53.83	09/08/2025		A		6,227		09/08/2026	09/08/2035	Common Stock	6,227	$0	6,227	D(2)

Explanation of Responses:

1. Each restricted stock unit ("RSU") represents a contingent right to receive one share of common stock, par value $0.01 per share of ConMed Corporation (the "Company") and will be subject to the terms and conditions of the Company's 2025 Long-Term Incentive Plan, with the RSUs generally vesting 100% after a one year period.

2. The stock options were granted under the 2025 Long-Term Incentive Plan of CONMED Corporation (the "Company) and generally vest 100% 1 year from the grant date.

	/s/ Thomas Fistek for Kim Kelderman by Power of Attorney	09/09/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What equity awards did CONMED director Kim Kelderman receive on 09/08/2025?

The Form 4 reports 500 RSUs and 6,227 stock options granted on 09/08/2025.

When do the RSUs and options granted to Kim Kelderman vest and become exercisable?

Both the RSUs and the options generally vest 100% one year from the grant date; the options are exercisable beginning 09/08/2026.

What is the exercise price and expiration date of the options granted to Kim Kelderman?

The options have an exercise price of $53.83 per share and expire on 09/08/2035.

How many shares does the Form 4 show as beneficially owned after the grants?

The filing shows beneficial ownership of 500 shares underlying RSUs and 6,227 option shares, reported as direct holdings.

Under which plan were the awards granted?

The RSUs and options were granted under CONMED Corporation's 2025 Long‑Term Incentive Plan.